טוען...
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
BACKGROUND: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), tafamidis reduces all-cause mortality and cardiovascular hospitalizations, and slows decline in quality-of-life compared with placebo. In May 2019, tafamidis received expedited approval from the US FDA as a breakthrough dru...
שמור ב:
| הוצא לאור ב: | Circulation |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7156331/ https://ncbi.nlm.nih.gov/pubmed/32078382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.045093 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|